787 related articles for article (PubMed ID: 27757389)
1. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
2. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
4. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
5. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review.
Kaako A; Al-Amer M; Abdeen Y
Anaerobe; 2019 Feb; 55():112-116. PubMed ID: 30521856
[TBL] [Abstract][Full Text] [Related]
6. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
7. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
8. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
[TBL] [Abstract][Full Text] [Related]
9. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
10. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
11. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
12. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
[TBL] [Abstract][Full Text] [Related]
13. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
14. Update of treatment algorithms for Clostridium difficile infection.
Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
[TBL] [Abstract][Full Text] [Related]
16. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Bezlotoxumab Immunogenicity.
Montgomery DL; Matthews RP; Yee KL; Tobias LM; Dorr MB; Wrishko RE
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):330-340. PubMed ID: 31411386
[TBL] [Abstract][Full Text] [Related]
18. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Lv Z; Peng G; Liu W; Xu H; Su J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
[TBL] [Abstract][Full Text] [Related]
20. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
Deeks ED
Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]